

CLAIMS


1. Use of a compound selected from the group consisting of



(II),



(Ib),




(Ic),

and its pharmaceutically acceptable salts and/or solvates thereof,


in the preparation of a medicament in the treatment of autosomal dominant polycystic kidney disease (ADPKD).

2. The use of claim 1, wherein the compound is of formula (II)




(II), or a pharmaceutically acceptable salt and/or solvate thereof

3. The use of claim 2, wherein the compound is of formula (II)



(II), or a pharmaceutically acceptable salt and/or hydrate thereof.

4. The use of claim 2, wherein the compound is the monohydrate potassium salt of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ia):



(Ia).

5. The use according to any one of claims 1 to 4, wherein the compound is to be administered once or twice a day at a daily dose of 0.5mg to 3000 mg for a human patient.

6. The use according to claim 5, wherein the compound is to be administered once or twice a day at a daily dose of 20 mg to 1000 mg.

7. The use according to claim 6, wherein the compound is to be administered once or twice a day at a daily dose of 60 mg to 500 mg.

8. The use according to any one of claims 1 to 7, wherein said compound is effective for preventing or limiting cyst growth or reducing cyst volume.

9. The use according to any one of claims 1 to 8, wherein the medicament is to be administered by oral route.